Phase 4 Asthma Trial, Recruiting NCT07241117 Sponsor: Washington University School of Medicine Condition: Asthma
Back to Asthma

Phase 4 Asthma Trial, Recruiting

NCT07241117
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Clinics:

  • The clinic must be an active participant in the St. Louis Integrated Health Center Network for Community Academic Partnerships.
  • The clinic must employ at least 3 clinicians who regularly manage adult asthma patients (meaning they see at least one adult asthma patient per week on average).
  • The clinic must share data with a system called Azara for reporting purposes.
  • The clinic must be willing and able to take part in all parts of the SMART program, which includes educational visits, ongoing coaching and support, regular review of patient outcomes and feedback, patient education materials, asthma action plans, and monthly meetings.

Doctors and clinical staff:

  • The person must have signed and dated a consent form agreeing to take part.
  • The person must hold a current state licence as a physician, assistant physician, nurse practitioner, or physician assistant.
  • The person must regularly care for adults who have asthma (this may include those trained in family medicine, internal medicine, obstetrics/gynecology, or specialist medicine).
  • The person must be willing and able to incorporate the SMART program into how they practise.
  • The person must be willing and able to take part for the full length of the study, including all phases.
  • The person must be willing to share data about their prescribing habits and their asthma patients' outcomes throughout the study.

Patients:

  • Patients who are aged 12 years or older may be considered.
  • Patients with a formal diagnosis of asthma of any severity, recorded using the standard medical coding system, may be considered.
  • Patients who have had 2 or more asthma attacks in the past year that required steroid treatment, and/or patients with an active prescription for certain types of asthma inhalers (medium or higher dose steroid inhalers, or low or higher dose combination steroid and long-acting reliever inhalers, along with a short-acting reliever inhaler) may be considered.

Who may not be able to join:

  • Clinics that do not meet all four of the clinic-level requirements listed above may not be eligible to participate.
  • Clinicians or staff who do not hold a current valid state licence in one of the listed roles may not be eligible to participate.
  • Patients under the age of 12 may not be eligible to participate.
  • Patients without a formally recorded asthma diagnosis, or who do not meet the prescribing or exacerbation history requirements, may not be eligible to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 3143769452

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
6 January 2026
Est. completion
15 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Patient-level Effectiveness (of the SMART implementation bundle); Clinician-level adoption (of the SMART implementation bundle)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov